Q3 net sales grew +4% (cc ¹, +4% USD), with core operating income ¹ +10% (cc, +11% USD) Sales growth driven by priorit ...
MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...
“The clinically meaningful overall survival benefit observed in NATALEE underscores Kisqali as a standard of care for eligible patients and its foundational role in early breast cancer treatment,” ...
Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6 Approval ...
Novartis ranked #19 in TIME and Statista's World's Best Companies 2026, rising from #114, based on employee satisfaction, growth and sustainability.
Nürnberg, 06. Juli 2026 – Tatjana Dreyer hat zum 1. Juli 2026 die Position als Head Communications & Patient Advocacy bei Novartis Deutschland übernommen. In dieser Funktion gehört sie dem… ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results